DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Transactions / D••••••
••• Locked
Add-on acquisitionclosedadd-onannouncement date unknownFact
What happened
- Target
- D••••••
- Platform
- B•• G••••add-on basis: B•• G••••, the world’s leading independent provider of immuno-diagnostic reagents and contract services, has today announced the acquisition of D••••••, a leading supplier of autoimmune antigen products. | B•• G•••• is held by E••••••• P•••••• E••••• on its portfolio page; published on E••••••• P•••••• E•••••'s own news page
- Control
- Control
- Share acquired
- unknown
- Industry
- unknown
- Target location
- unknown
- Seller kind
- unknown
- Rollover
- unknown
Values, only where disclosed
- Enterprise value
- Not disclosed
- Purchase price
- Not disclosed
- Equity value
- Not disclosed
- Target revenue
- Not disclosed
- Target EBITDA
- Not disclosed
- Multiple
- Not disclosed
Parties and roles
4 named
Buy side
- “••• Locked”
- “••• Locked”
Side not stated
- “••• Locked”
- “••• Locked”
Evidence
“••• Locked”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026